---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115724"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:37:00.268550+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates

## Summary
- Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.
- Phase 1a dose escalation of NXP800 ongoing; Phase 1b expansion expected to start Q1 2023.
- IND-enabling studies for NXP900 ongoing; IND or equivalent submission expected Q1 2023.
- Positive preclinical data for NXP800 in ARID1a-mutated gastric cancer model.
- Cash runway into H2 2024; formed Scientific Advisory Board.

## SEC filing metadata
- accession: 0001104659-22-115724
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/0001104659-22-115724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/tm2229896d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115724
- JSON: https://secwatch.observer/filing/0001104659-22-115724.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115724.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/0001104659-22-115724-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.